Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives

Abstract:
Approximately 5%–10% of asthmatics suffer from severe asthma. New biological treatments represent a great opportunity to reduce asthma burden and to improve asthma patients’ lives. Reslizumab will soon be available in several European countries. This anti-IL-5 IgG4/κ monoclonal antibody, administered intravenously at a dose of 3 mg/kg over 20–50 minutes every 4 weeks, has been shown to be safe and effective in patients with 400 eosinophils/μL or more in their peripheral blood. The clinical effects in reducing asthma exacerbations and in improving the quality of life and lung function are clear, but further research is needed to determine the best biological compound for a specific cluster of patients. Research data have shown that in patients who were expressing other clinical features of eosinophilic inflammation over asthma (rhinosinusitis and nasal polypsis), the clinical benefit of reslizumab was greater. Furthermore, it has also been observed that in patients with unsatisfactory response to mepolizumab, reslizumab is able to significantly improve the clinical and biological parameters. The aim of personalized medicine is to provide the right drug to the right patient at the right dose at the right moment. The biological treatments that were developed to modify specific pathological pathways not only provide us with the tools for the management of asthma patients but also clarify the biological mechanisms involved in its pathogenesis.

Keywords: asthma, patient-reported outcomes, personalized medicine, reslizumab

Reslizumab in the context of personalized medicine of severe asthma

According to the current estimates, asthma is globally the most prevalent chronic respiratory disease affecting more than 358 million people and its incidence is still increasing.1 The introduction of international guidelines (Global Initiative for Asthma, GINA)2 for the management of asthma in 1993 and their implementation into clinical practice have not only significantly altered the burden of the disease but also revealed the areas of inadequate treatment control and unmet needs. The significant heterogeneity of asthma leads to the identification of various asthma phenotypes. The problem of severe asthma emerged more clearly when the management strategy introduced the focus on asthma control.3 Severe asthma is defined as “asthma which requires treatment with high dose inhaled corticosteroids (ICSs) plus a second controller (and/or systemic corticosteroids) to prevent it from becoming “uncontrolled” or which remains “uncontrolled” despite this therapy”.4 The prevalence of severe asthma is reported to be around 5% with high rate of poor control (>50% of patients) with a significantly higher risk of exacerbations (risk ratio 2.59) and a low level of health-related quality of life.
of life (HRQoL). Although the prevalence of severe asthma is low, the burden of the disease on the patient, family, health care system, and society is disproportionally high, accounting for up to 30% of all costs incurred by all asthmatic patients. Solving the problem of severe asthma is complicated due to the fact that it is a heterogeneous condition presenting with different phenotypes that are based on distinct endotypes.

Various studies have identified several phenotypes of severe asthma primarily based on a different set of input parameters, but ~50% of severe asthma patients have elevated eosinophil levels and certain level of resistance to corticosteroid treatment. Both these characteristics are associated with increased burden (lower rate of control, higher rate of exacerbations, and adverse events) and costs of asthma (>double). Based on this fact, a corticosteroid sparing strategy that would down-regulate the high level of eosinophils could produce benefits on disease control and reduce its burden. Both the innate and adaptive immunity pathways of type-2 airway inflammation (“Th2-high asthma” phenotype) are involved with many cell types and signaling molecules. In severe eosinophilic asthma, interleukin-5 (IL-5) has been found to be one of the major players in the recruitment of eosinophils; therefore, biological drug–targeting strategies have been developed by using humanized monoclonal antibodies (hmAbs). Of the two hmAbs that have been created, one binds to IL-5 preventing from binding to its receptor (mepolizumab and reslizumab) and the other (benralizumab) binds to IL-5 alpha chain receptor (IL-5Rα). Both mepolizumab and reslizumab have been shown to be clinically effective, allowing for a precision medicine approach targeting a specific pathway. Nowadays, the use of novel research technologies (genomics, transcriptomics, proteomics, and metabolomics) allows us to define heterogeneity among patient subgroups and among individual patients on the basis of a specific pathophysiological patterns, networks of effector cells, and signaling molecules, allowing us to specifically target these pathways. Although it might seem that precision and personalized medicine are synonyms, this is not the case. Unlike precision medicine that targets specific endotypes or major endotypes behind specific phenotypes in a (sub)group of patients, personalized medicine is an individually tailored treatment. Meanwhile, specific markers like blood and sputum eosinophils, fraction of exhaled nitrous oxide, periostin, and even recent omics approaches allow only a precision medicine approach.

As with other medicines, an individual response to different drugs of the same class is to be expected. Strategies to decode the pathophysiological mechanisms behind the specific phenotype in individual patients using the newest omics sciences will allow a personalized approach to individual patients. However, to develop such strategies, we would need the records of patients who were treated with specific biological agents, like reslizumab, supported with biobanks and high-throughput omics technologies.

### Biological properties of anti-IL-5 molecules

Reslizumab is a humanized IgG4/k mAb produced by means of a synthetic process based on recombinant technology, which allows the integration of the rat antigen recognition sites for human IL-5 to a human IgG4. The antibody can bind free IL-5 molecules (dissociation constant = 81 pM; association constant of $4.9 \times 105$ per M/s). This bonding prevents IL-5 from linking to its receptor. It is of fact that reslizumab at a concentration of 0.5 nM inhibits IL-5 binding by 50% and at 45 nM inhibits IL-5-induced proliferation by 50%. Reslizumab has been tested in animal models featuring eosinophilic inflammation, such as allergic mice and ascarsis-responsive monkeys. The effect of the drug lasted for 6 months after administration in monkeys, thereby reducing the ascars challenge-induced eosinophilia by 75%. In ovalbumin-sensitized guinea pig model, reslizumab (0.03 mg/kg and 1 mg/kg) administered 2 hours before the specific challenge reduced eosinophilia, airway hyperreactivity, and bronchoconstriction. In ovalbumin-sensitized rabbits, reslizumab decreased the eosinophil influx into the skin without impacting the overall number of cells in the skin. The aforementioned data justify the in vivo investigation that demonstrated that reslizumab reduces airway hyperresponsiveness and inhibits the influx of eosinophils into the lungs. For example, in animals exposed to an agent that increases the eosinophil count to 298,000 cells/mL, a 1 mg/kg dose reduced eosinophil in the bronchoalveolar lavage counts to 108,000 cells/mL. Furthermore, in the Phase II Res-5-0010 study, reslizumab significantly lowered the active airway eosinophilic inflammation by reducing the sputum eosinophil count by 95% compared with a 39% reduction for placebo. At present, the anti-IL-5 mAb families also include mepolizumab, while benralizumab binds to the surface of IL-5 receptor. Mepolizumab, unlike reslizumab, is a humanized IgG1. Mepolizumab is composed of 4 light and heavy chains linked by a disulfide bridge. The antibody binds with high-specificity and -affinity IL-5 ($IC_{50} < 1$ nM; $K_a = 4.2$ pM) and avoids binding to IL-5Rα. Both mepolizumab and reslizumab bind to epitopes within the IL-5Rα-binding domain, while mAbs interacting with IL-5βc domain are currently not available, although this may represent a potential target.
Functional and biological results from pivotal trials

Reslizumab has been recently approved for the treatment of severe eosinophilic asthma. This is due to its safety profile and efficacy. The first study that showed the efficacy of the drug in reducing eosinophils in asthmatics was conducted by Kips et al. The pilot investigation was carried out in a small number of subjects (n = 32) who were suffering from severe persistent asthma despite high-dose ICSs or systemic corticosteroids and they were treated with placebo or reslizumab intravenously (IV). No significant effect on eosinophil counts was observed in patients treated with lower doses, whereas a sustained response was observed in those treated with the highest dose. Interestingly, there were no significant differences in lung function or symptom scores among the study groups. These disappointing findings can be reasonably explained by the “small and not powered” study population and by the lack of preselection of patients with eosinophilia.

To overcome this issue, a multicenter, randomized, double-blind, placebo-controlled study was designed to explore the effects of reslizumab versus placebo in poorly controlled adult asthmatics with induced sputum eosinophils of 3% or more. As expected, patients who received reslizumab had a significant decrease in sputum eosinophils. An improvement from baseline in forced expiratory volume in 1 second (FEV1) was found in the reslizumab group compared with placebo. In addition, a trend for improvement in asthma control and reduction in exacerbation rates was shown in the active group, although it was not statistically significant.

Two subsequent studies had the merit of including blood eosinophil count instead of sputum eosinophils to define eosinophilic asthma, thus limiting the intrinsic variability due to the difficulties in collecting sputum from severe asthmatics and lack of reproducible findings. Two other trials assessed the efficacy of reslizumab in severe asthmatics. A total of 953 patients received reslizumab at a dose of 3 mg/kg or placebo IV every 4 weeks (Q4W) for a total of 13 doses. Patients in the active group showed early improvements in lung function and in symptoms, as well as a reduction in asthma exacerbations compared with placebo. Corren et al investigated the efficacy of reslizumab in a cohort of 496 uncontrolled asthmatic subjects with a wide range of blood eosinophil concentrations. The efficacy of reslizumab in terms of improvements in pulmonary function, as well as in terms of Asthma Control Questionnaire (ACQ) scores and rescue inhaler use, was detected only in subgroup analyses in subjects with eosinophil counts ≥400/L.

Patient-reported outcomes (PROs) results from pivotal trials

PROs – “any report coming from patients about a health condition that comes directly from the patient, without interpretation of the patient’s response by a clinician or anyone else” – allow to capture a patient’s subjective perspective on the effectiveness of a treatment. As such, PROs provide the possibility to include the input coming from patients in assessing the impact of a treatment and may personalize the treatment decision-making process. All the registered studies evaluating the efficacy and safety of reslizumab in asthma patients include the assessment of PROs as primary or secondary outcomes. In the study by Castro et al, the primary end point was the change of asthma control (assessed by ACQ-7) in patients who were treated with reslizumab or placebo for 15 weeks. The mean change in ACQ-7 score from baseline to the study end was modest and did not achieve statistical significance (−0.7 in the reslizumab group and −0.3 in the placebo group, p = 0.0541). A subgroup analysis of patients with comorbid nasal polyposis detected a significantly greater improvement in ACQ-7 scores in the active group than in placebo group (−1.0 vs −0.1, p = 0.0119). The minimal important difference (MID) of 0.5, which represents the smallest change perceived as beneficial by patients, was achieved in 59% of patients in the reslizumab group and in 40% of patients in the placebo group (odds ratio: 2.06, p = 0.0973). The results of the two parallel studies described by Hart et al showed that the significant effect of reslizumab on the primary outcome (frequency of asthma exacerbations) moves in parallel with the effect on PROs. As a matter of fact, the scores of Asthma Quality of Life Questionnaire (AQLQ), ACQ-7, and Asthma Symptom Utility Index (ASUI) show a significantly greater improvement (p < 0.05) in the active group compared with placebo. Moreover, compared to placebo group, a higher percentage of patients in the reslizumab group reached the MID in AQLQ (study 1: 74% vs 65%, p = 0.03; study 2: 73% vs 62%, p = 0.02) and in ACQ-7 (study 1: 76% vs 63%, p = 0.0002; study 2: 77% vs 61%, p = 0.0002). Corren et al showed that the mean change of ACQ-7 score was modest from baseline to the end of the study (week 16) and the differences between reslizumab and placebo groups did not reach statistical significance. However, the percentage of patients who reached the MID was significantly higher with reslizumab than with placebo (71% vs 57%, p = 0.01). Moreover, a secondary analysis in the subgroup of patients with a blood eosinophil count of ≥400 cells/mL detected a small but significant improvement
with reslizumab treatment compared with placebo treatment (0.272 vs 0.002, \( p = 0.0436 \)), corresponding to the improvement in FEV1. Both reslizumab 0.3 mg/kg and 3.0 mg/kg\(^29\) significantly improved asthma control (ACQ-7) and frequency and severity of symptoms (ASUI) compared with placebo. Both the tools detected a greater magnitude of improvement in the group treated with reslizumab 3 mg/kg. At the end of the study, MID of ACQ-7 was reached by a similar percentage of patients in the reslizumab and placebo groups, without any significant difference among the groups. Improvements in AQLQ scores versus placebo were observed for reslizumab 3 mg/kg (1.138 vs 0.779, \( p = 0.0241 \)) but not for reslizumab 0.3 mg/kg (1.057 vs 0.779, \( p = 0.0822 \)). A greater proportion of patients in the active groups compared to placebo group achieved the MID of AQLQ at the study end. The difference versus placebo was significant for reslizumab 3 mg/kg (64% vs 48%, \( p = 0.0189 \)) but not for reslizumab 0.3 mg/kg (59% vs 48%, \( p > 0.05 \)).

**Placement of reslizumab in biological treatment of asthma**

Reslizumab administered by IV perfusion has demonstrated a notable effect, compared to placebo, in reducing exacerbations and in triggering significant improvements in pulmonary function in adult patients with severe eosinophilic asthma (baseline levels of eosinophils \( \geq 400 \) cells/μL) that remains inadequately controlled despite being treated with high doses of ICS + long-acting beta-agonists and/or oral corticoids.\(^{22,27–29}\) It should be noted that clinical trials on mepolizumab and reslizumab have produced similar results, but the studied populations have never been exactly the same. However, in the absence of any direct comparisons, it is impossible to establish the differences (or otherwise) between these two drugs, although reslizumab, unlike subcutaneous mepolizumab, could be limited by the need for IV administration but could provide a greater sense of care to the patient. Moreover, no specific studies have confirmed the effect of reslizumab on reducing the use of oral corticoids, whereas these data are available in the case of mepolizumab.\(^{28,29}\) These limitations must be considered before selecting treatment. More recently, however, a study investigated 10 prednisone-dependent asthmatics (blood eosinophils \( \geq 300 \) cells/μL and sputum eosinophils \( \geq 3\% \)) who had previously received mepolizumab (100 mg subcutaneous dose Q4W) for at least 1 year and two infusions of placebo (Q4W) followed by 4 infusions of 3 mg/kg reslizumab Q4W, in a single-blind, placebo-controlled sequential trial.\(^{40}\) The authors found that the weight-adjusted IV reslizumab was superior to the fixed-dose subcutaneous mepolizumab in attenuating eosinophilia. Attenuation of both local and systemic eosinophilia was associated with statistically significant improvements in asthma control and FEV1. Reslizumab could, therefore, be also used as an alternative for those patients who show no improvement with mepolizumab. In 2016, Froidure et al\(^{41}\) created a decision chart to aid the selection of appropriate biological treatment, based on the levels of IgE and eosinophilia in the blood, but there is currently some controversy concerning the mAb that should be first used in case of allergic and eosinophilic asthma. Some authors have suggested that omalizumab should be used as the first option in patients with an allergic phenotype, regardless of the levels of eosinophils in the peripheral blood, with anti-IL-5 as an alternative for allergic patients with blood eosinophilia in whom omalizumab treatment has failed.\(^{42}\) A recently published post-hoc analysis\(^{43}\) of two 52-week placebo-controlled trials of reslizumab IV 3 mg/kg every 4 weeks in patients with uncontrolled asthma has compared the results for pulmonary function and exacerbations in patients with late-onset asthma to those with early onset asthma. This analysis showed that reslizumab produced greater improvements in lung function and larger reductions in asthma exacerbations in patients with late-onset asthma compared to those with early onset asthma. This could be an important consideration when deciding on biological treatment. Although no studies have been undertaken to compare such findings with the efficacy of omalizumab in patients with late-onset asthma, the results of the aforementioned analysis suggest that the use of anti-IL-5 could be posited as a first option for allergic and eosinophilic patients with late-onset asthma. An algorithm for treatment has been created based on phenotypes by Domingo\(^{42}\) and Alvarez et al,\(^{44}\) but the value of these approaches needs to be explored in real life. Other factors that possibly need to be considered before choosing a mAb are asthma severity and pulmonary function. A recent study has published pooled data from duplicate, Phase III, reslizumab versus placebo trials, in which patients were categorized according to severity (Steps 4 and 5 of the GINA guidelines). This study showed that, compared with placebo, reslizumab has increased FEV1 in Step 4 and Step 5 groups by 103 mL (52–154 mL) and 237 mL (68–407 mL), respectively. Additionally, reslizumab reduced exacerbation rates by 53% (0.36–0.62) and 72% (0.15–0.52) in Step 4 and Step 5 groups, respectively.\(^{45}\) Furthermore, reslizumab has been shown to improve nasal polyposis in patients with severe asthma.\(^{46}\) Some meta-analyses have also demonstrated the beneficial effects of anti-IL-5 in patients with refractory polyposis and of omalizumab in patients with polyposis and severe asthma.\(^{47}\) No studies have yet directly
compared the effects of reslizumab on nasal polyposis with that of other anti-IL-5 or omalizumab, and so specific studies are required to identify the most suitable first-choice treatment in this respect.

**Is there a need for new data?**

The introduction of specific biological therapies, such as anti-IgE and anti-IL-5 antibody treatments, at Step 5 of the GINA guidelines has opened a new era of precision medicine in asthma since these agents targeted specific severe asthma pathways, either allergic or eosinophilic.48 The IL-5 neutralizing antibodies mepolizumab and reslizumab were licensed in the USA and Europe following successful Phase III studies that demonstrated reduced asthma exacerbations frequency and improved baseline airflow obstruction27,49 in patients with high blood eosinophil levels. Another immunomodulator that mediates the effect of IL-5 is benralizumab, an antibody directed against IL-5Rα, which showed beneficial effects on exacerbations and lung function, particularly in those with increased blood eosinophil count.30 Unfortunately, currently, we do not have a comparative study of these biological therapies in terms of effectiveness and tolerability. A recent Cochrane meta-analysis51 including 13 studies on 6000 participants (4 with mepolizumab, 4 with reslizumab, and 5 with benralizumab) supports the use of anti-IL-5 treatments as an adjunct to standard therapies in patients with severe eosinophilic asthma and poor control on the basis that these treatments roughly halve the rate of asthma exacerbations in this population. However, the authors concluded that there is limited evidence for improved HRQoL scores and lung function in patients treated by anti-IL-5. The safety profile of anti-IL-5 treatment is acceptable since and high rate of serious adverse events has not been registered. In this meta-analysis, the number of adverse events leading to discontinuation in mepolizumab or reslizumab was similar to placebo, but significantly higher compared to placebo when benralizumab was interrupted (36/1599 benralizumab vs 9/998 placebo). A possible explanation may be that mepolizumab and reslizumab markedly decrease blood eosinophils but a small number remains, whereas benralizumab almost completely deplete the eosinophils. The implications for efficacy and/or adverse events are still unclear, although benralizumab data are intriguing.51 Some relevant results are also available on dupilumab. This mAb is directed against the α-subunit of IL-4 receptor that can block signaling from IL-4 and IL-13. It is shown that dupilumab given subcutaneously can increase lung function and reduce severe exacerbations in patients with uncontrolled persistent asthma, even in patients with low blood eosinophil levels. The transient increase of blood eosinophil during the treatment with this drug needs to be further investigated.52 Post-licensing real-life studies are needed to establish the effectiveness and tolerability of these therapies, their optimal duration, long-term benefits and adverse effects, risk of relapse on withdrawal, and the effect in non-eosinophilic patients and children (particularly under 12 years). The comparison of various anti-IL-5 treatments with anti-immunoglobulin E (omalizumab) in patients eligible for both is needed. For benralizumab, future studies should be undertaken to establish the rates of adverse events prompting discontinuation.51,53 In the new era of precision medicine in severe asthma, there is an increasing need for developing biomarkers that will guide clinicians in the management of asthma. For the clinician to understand how to select the right therapy for the right patient, we also need more phenotypic and predictive biomarkers for assessing the treatment response. For anti-IL-5 therapies, we probably need to look beyond elevated blood eosinophil counts as a predictive factor.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


Impact of reslizumab on asthmatic patient outcomes